Latest News

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Does facial massage with a gua sha improve skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.

Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.

The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending.

This review of the latest dermatological studies includes insights on fibromyalgia in rosacea patients, isotretinoin use and suicidality in adolescents, patient-centered teledermatology, and more.